How the Latest Guidelines Are Changing the Diagnostic and Therapeutic Landscape of Arterial Hypertension

Abstract

Arterial hypertension (HTN) represents the major cardiovascular risk factor and still represents a global health issue. In the last two years, three international societies published the new guidelines for the treatment of HTN (European Society of Cardiology, 2025; European Society of Hypertension, 2023; and American College of Cardiology in collaboration with American Heart Association, 2025), with many novelties which have been the object of many discussions among experts. The increased stress on screening programs, the new lower targets to reach by medical treatment, and the new strategies for resistant hypertension have raised some doubt on the feasibility of these recommendations in clinical practice. In this perspective document, the authors highlight and discuss the novelties and potential pros and cons of the new international recommendations for the treatment of arterial HTN.